RMC No. 101-2020 — Publishes the full text of the letter from the Food and Drug Administration of the Department of Health containing the “Addendum to the List of VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol” pursuant to RA No. 11467 Digest | Full Text | FDA Letter | Addendum to List of Drugs

BUREAU OF INTERNAL REVENUE REPUBLIC OF THE PHILIPPINES DEPARTMENT OF FINANCE

SEP 2 1 2020

REVENUE MEMORANDUM CIRCULAR NO.- 1D1- & D 20

SUBJECT: Publishing the Full Text of the Letter from the Food and Drug Administration (FDA) of the Department of Health (DOH) Containing the "Addendum to the List of VAT-Exempt Drugs for

Hypertension, Diabetes and High Cholesterol" Pursuant to Section 1 of Republic Act No.11467

TO All Internal Revenue Officers and Others Concerned

concerned, attached is the letter dated May 28, 2020 from Rolando Enrique D. Domingo, For the information and guidance of all internal revenue officers, employees and others

Director General of the FDA, and the copy of the "Addendum to the List of VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol".

the initial list of VAT-exempt drugs for hypertension, diabetes and high cholesterol provided by the said government agency in their letter dated March 2, 2020. This is a supplement to Revenue Memorandum Circular No. 62-2020, which published

All concerned are hereby are enjoined to be guided accordingly and give this Circular as wide a publicity as possible.

C

BUREAUOFINIERNALKEVFNUE SEP. 2 5 2020 3:14 P.M. NTYN Commissioner of Internal Revenue CAESAR R. DULAY 03654 2

T JCE RECORDS MGT. BIVIS"N